Clinical trial of anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19
Multicenter, randomized, double-blind, placebo-controlled, non-commercial clinical trial aiming
to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19
CLINICAL TRIAL
Dear Sir/Madam,
We invite you to participate in the clinical trial entitled: "Multicenter, randomized, double-blind, placebo-controlled, non-commercial clinical trial aiming to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19", which aims to investigate the safety and efficacy of specific anti-SARS-CoV-2 immunoglobulin administered intramuscularly in hospital settings, along with standard symptomatic treatment according to scientific society/AOTMiT/SOP guidelines, in patients with SARS-CoV-2 infection.
Please log in to start entering patient observation data.
